Using Real-World Evidence to Accelerate Drug Approvals for Rare Diseases
The first-line therapy indication for metastic Merkel cell carcinoma (mMCC) was completed using real-world data and insights1 to gain the first-ever FDA approval for this rare disease.
Please fill out the form to download the Case Study: